A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.

Haines, I; Elliott, P; Stanley, R

Haines, I; Elliott, P; Stanley, R.

Intern Med J ; 39(4): 269-71, 2009 Apr.

Article in En | MEDLINE | ID: mdl-19402870

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Practice Guidelines as Topic; Antimetabolites, Antineoplastic/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/economics; Chlorambucil/therapeutic use; Conflict of Interest; Cost-Benefit Analysis; Cross-Over Studies; Cyclophosphamide/administration & dosage; Cyclophosphamide/adverse effects; Cyclophosphamide/economics; Disease-Free Survival; Drug Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/economics; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Vidarabine/administration & dosage; Vidarabine/adverse effects; Vidarabine/analogs & derivatives; Vidarabine/economics; Vidarabine/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Practice Guidelines as Topic Type of study: Clinical_trials / Guideline / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Intern Med J Journal subject: MEDICINA INTERNA Year: 2009 Document type: Article Country of publication: Australia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google